methyl 2-(p-acetylphenoxy)-2-methylpropionate | 42019-06-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 2-(p-acetylphenoxy)-2-methylpropionate
• 英文别名: methyl 2-(4-acetylphenoxy)isobutyrate；Methyl 2-(4-acetylphenoxy)-2-methylpropanoate
• CAS: 42019-06-7
• 化学式: C₁₃H₁₆O₄
• 分子量: 236.268
• InChiKey: LWLRITLSGGNJTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-(p-acetylphenoxy)-2-methylpropionate 在 水 、 sodium methylate 、 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 2-(4-hydroxyphenoxy)-2-methylpropionic acid methyl ester
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016
• 作为产物：
  描述：

  2-氯-2-甲基丙酸甲酯 在 aluminum (III) chloride 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 methyl 2-(p-acetylphenoxy)-2-methylpropionate
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016

文献信息

• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05556977A1

  公开（公告）日：1996-09-17

  Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

  公式I的化合物及其代谢易降解的酯和酰胺，以及其药学上可接受的盐，其中R.sup.13，M.sup.2，X.sup.1，Z.sup.1，Z.sup.1a，X.sup.2和A.sup.1具有规范中给定的含义。这些化合物可用作抑制纤维蛋白原与糖蛋白IIb/IIIa结合的抑制剂。还披露了中间体。
• Halocyclopropyl substituted phenoxyalkanoic acids
  申请人：Sterling Drug Inc.

  公开号：US03948973A1

  公开（公告）日：1976-04-06

  Halocyclopropyl substituted phenoxyalkanoic acids and esters thereof, having hypocholesteremic activity are prepared via several alternative synthetic approaches, involving as the key reactions interaction of a substituted phenylalkene with a carbene source to introduce the halocyclopropyl moiety, and reaction of a substituted phenol with chloroform and a lower-alkanone in the presence of base, or with a lower-alkyl .alpha.-bromo-alkanoate, to form the phenoxyalkanoic acid moiety.

  含有降胆固醇活性的卤代环丙基取代的苯氧基烷酸及其酯类，可以通过几种替代合成方法制备，其中关键反应包括取代苯基烯烃与卡宾源相互作用以引入卤代环丙基基团，以及在碱存在下，取代酚与氯仿和较低的烷酮，或与较低烷基α-溴代烷酸酯反应，形成苯氧基烷酸基团。
• Heterocyclic derivatives as platelet aggregation inhibitors
  申请人：ZENECA LIMITED

  公开号：EP0825184A1

  公开（公告）日：1998-02-25

  RS 3-Methyl-4-[4-(4-pyridyl)piperazin-1-yl]phenoxybutyric acid and metabolically labile ester or amides thereof, and pharmaceutically acceptable salts thereof useful as an inhibitor of the binding of fibrinogen to glycoprotein IIb/IIIa.

  RS 3-甲基-4-[4-(4-吡啶基)哌嗪-1-基]苯氧基丁酸及其代谢易变酯或酰胺，以及可用作纤维蛋白原与糖蛋白 IIb/IIIa 结合抑制剂的药学上可接受的盐。
• HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS
  申请人：ZENECA LIMITED

  公开号：EP0691959A1

  公开（公告）日：1996-01-17
• HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS
  申请人：ZENECA LIMITED

  公开号：EP0690847A1

  公开（公告）日：1996-01-10